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Summary
Diffuse large B cell lymphomas (DLBCL) derive from germinal center (GC) B cells and display chromosomal alterations
deregulating the expression of BCL6, a transcriptional repressor required for GC formation. To investigate the role of BCL6
in DLBCL pathogenesis, we have engineered mice that express BCL6 constitutively in B cells by mimicking a chromosomal
translocation found in human DLBCL. These mice display increased GC formation and perturbed post-GC differentiation
characterized by a decreased number of post-isotype switch plasma cells. Subsequently, these mice develop a lympho-
proliferative syndrome that culminates with the development of lymphomas displaying features typical of human DLBCL.
These results define the oncogenic role of BCL6 in the pathogenesis of DLBCL and provide a faithful mouse model of this
common disease.S I G N I F I C A N C E
Diffuse large B cell lymphoma (DLBCL), the most common type of human B cell lymphoma, is poorly understood in its pathogenesis
and is incurable in a subset of cases. This is partly due to lack of knowledge about the role of BCL6, the gene that is most frequently
altered in DLBCL, and to the absence of animal models that recapitulate both the genetics and the biology of the disease. Here we
have engineered a mouse model of DLBCL that shows the specific role of BCL6 in its pathogenesis and displays most of the critical
features of the corresponding human tumor. This model can be used to test novel therapies targeted to BCL6.Introduction
The BCL6 proto-oncogene encodes a transcriptional repressor
required for the formation of germinal centers (GC) (Ye et al.,
1993a; Ye et al., 1997; Dent et al., 1997), the structures in
which mature B cells undergo somatic hypermutation (SHM) of
their immunoglobulin variable region (IgV) genes and Ig class-
switch recombination (CSR) before being selected based on
the production of antibodies with high affinity for the antigen
(Rajewsky, 1996). GCs are required for antibody-mediated im-
mune responses and are also important in pathology, since GC
B cells are thought to represent the cell of origin of most types
of human B cell lymphomas (Dalla-Favera and Gaidano, 2001;
Küppers et al., 1999). BCL6-deficient mice display normal B
cell development except for their inability to form GC (Dent et
al., 1997; Ye et al., 1997), consistent with the fact that, within
the B cell lineage, BCL6 is expressed only in the GC (Cattoretti
et al., 1995). BCL6 exerts its transcriptional repressor function
by binding to specific DNA sequences via its C-terminal zinc
finger domain and recruiting corepressor complexes through
two noncontiguous domains, a N-terminal POZ domain and a
second, less characterized domain in the middle portion of the
molecule (Chang et al., 1996; Seyfert et al., 1996).CANCER CELL : MAY 2005 · VOL. 7 · COPYRIGHT © 2005 ELSEVIER INC.The biologic function of BCL6 in the GC is presumably to
favor the sustained proliferation of B cells involved in GC for-
mation by modulating the transcription of genes involved in cell
activation, differentiation, and cell cycle arrest (Shaffer et al.,
2000; Niu et al., 2003; Tunyaplin et al., 2004). In addition, BCL6
binds the promoter region of the p53 tumor suppressor gene
and suppresses its transcription in GC B cells, perhaps as a
means to allow the DNA breaks necessary for SHM and CSR
to occur without eliciting a p53-mediated apoptotic response
(Phan and Dalla-Favera, 2004). BCL6 expression is regulated
by signals involved in the control of GC development, including
T cell-induced CD40 signaling, which downregulates BCL6 at
the transcriptional level, and antigen-induced B cell receptor
(BCR) signaling, which leads to BCL6 degradation by the
ubiquitin-proteasome pathway (Niu et al., 1998; Niu et al.,
2003). BCL6 activity is also regulated by acetylation, which in-
activates its transrepressive function by preventing the recruit-
ment of corepressor complexes (Bereshchenko et al., 2002;
Fujita et al., 2004). Post-GC B cells lack BCL6 expression, and
downregulation of its function is thought to be necessary for
the differentiation of B cells into plasma cells and memory B
cells.DOI 10.1016/j.ccr.2005.03.037 445
A R T I C L EThe BCL6 proto-oncogene was originally identified because
of its involvement in 3q27 chromosomal translocations, which
are found in w40% of cases of diffuse large B cell lymphoma
(DLBCL) and in 5%–10% of cases of follicular lymphoma (FL)
(Ye et al., 1993a; Ye et al., 1993b; Kerckaert et al., 1993; Lo
Coco et al., 1994). These translocations place an intact BCL6
coding domain under the influence of heterologous promoter
regions derived from a variety of alternative partner chromo-
somes (>20), including the immunoglobulin heavy (H) and light
(L) chain genes (Ye et al., 1995; Chen et al., 1998; Pasqualucci
et al., 2003a). Since these promoters allow for a broader
pattern of expression throughout B cell development than the
natural BCL6 promoter, the translocation results in deregulated
expression of the normal BCL6 protein. In addition, the 5# non-
coding region of BCL6 is targeted by SHM in normal GC B
cells as well as in GC-derived malignancies (Migliazza et al.,
1995; Pasqualucci et al., 1998; Shen et al., 1998; Peng et al.,
1999; Capello et al., 2000). While the functional significance of
most BCL6 somatic mutations remains unknown, in 13% of
DLBCLs (but not in normal GC B cells), these were found to
disrupt the negative autoregulatory circuit that normally con-
trols BCL6 expression by altering two BCL6 binding sites
within the first noncoding exon of the gene (Pasqualucci et al.,
2003b; Wang et al., 2002). Collectively, translocations and
exon1 mutations are observed in w50% of DLBCL cases,
where they are thought to prevent the downregulation of BCL6
expression that is normally associated with differentiation into
post-GC B cells. However, direct experimental evidence impli-
cating BCL6 in DLBCL pathogenesis is still lacking.
To directly test the role of deregulated BCL6 in DLBCL
pathogenesis, we have engineered mice to express a murine
BCL6 coding domain under the control of the immunoglobulin
I promoter, thereby recapitulating the outcome of one of the
translocations associated with human DLBCL. Our results de-
monstrate a direct role for BCL6 in DLBCL development and
provide a model to study the biology of this disease and to test
novel therapeutic approaches.
Results
Construction of mice expressing deregulated BCL6
To obtain deregulated BCL6 expression in mouse B cells in vivo,
we used homologous recombination to insert a HA-tagged,
full-length murine BCL6 coding sequence downstream of the
immunoglobulin heavy chain (IgH) I promoter on mouse chro-
mosome 12 in murine ES cells. The recombinant locus can pro-
duce a chimeric mRNA (I-HABCL6) whose transcription is
driven by the I promoter, which is normally active in mature B
cells (Lennon and Perry, 1985), thereby mimicking one of the
chromosomal translocations, t(3;14)(q27;q32), occurring in hu-
man DLBCLs (Figure 1A) (Ye et al., 1995). Three independent
mouse lines were generated (4E12, 5H7, 4B8); in all of them,
mice heterozygous or homozygous for the manipulated allele
were born as expected for Mendelian transmission (Figure 1B
and data not shown), and were indistinguishable at birth from
their wt littermates. IHABCL6 mice were fertile, showed no
gross developmental abnormalities in all organs analyzed, and
displayed a normal B cell repertoire (not shown).
Northern blot analysis of mice between 8 and 12 weeks of
age after immunization with sheep red blood cells (SRBC) doc-
umented the presence of a transcript corresponding to the size446predicted for the knockin allele in purified splenic CD19+ cells
from the IHABCL6 mice, but not in other tissues or in wt litter-
mates (Figure 2A, left panel). Accordingly, Western blot analysis
with an anti-HA antibody, which can detect only the exogenous
tagged BCL6 protein, revealed a specific band exclusively in
the IHABCL6 splenic CD19+ B cell population (Figure 2A,
right panel). Both exogenous and endogenous proteins were
recognized by the anti-BCL6 antibodies, which showed BCL6
positivity in thymus and CD19+ B cells from both wt and
IHABCL6 mice, as expected.
We then characterized the topological distribution of BCL6
expression by immunohistochemistry (IHC) using antibodies
recognizing the exogenous (anti-HA) or both the endogenous
and exogenous (anti-BCL6) BCL6 protein. After immunization
with SRBC, both IHABCL6 and wt littermates formed BCL6-
positive GCs surrounded by mantle zone and marginal zone B
cells in which BCL6 is not detectable by IHC. However, a num-
ber of strongly BCL6-positive cells were also detected outside
the GC in the IHABCL6 mice, but not in control mice (Figure
2B, top panels). Staining for HA and PNA (a GC marker, not
shown) demonstrated expression of the exogenous protein
within—as well as outside—the GC of IHABCL6 mice (Figure
2B, bottom panels). These cells, which were not observed in
wt animals, represented differentiated plasma cells, as demon-
strated unambiguously by their morphologic features, coex-
pression of the specific marker CD138, and production of cyto-
plasmic heavy chain immunoglobulins of all isotypes (see
Figures 2C–2E for representative data; note that double IHC
analysis with other plasma cell markers such as BLIMP-1 and
XBP-1 [Lin et al., 2003] is not technically feasible with currently
available reagents). Deregulated expression of BCL6 in plasma
cells was further documented by double IHC and double im-
munofluorescence staining of the intestinal lamina propria—
where these cells localize in large numbers—using CD138/
BCL6, CD138/HA, and cytoplasmic IgA/BCL6 or IgG1/BCL6
antibodies (Figures 2C–2E). However, it was noted that only a
fraction (w15%) of plasma cells expressed BCL6 at high
levels; this may be due to the nonhomogeneous activity of the
I promoter in plasma cells as well as to recombination events
(deletions and mutations) occurring in the region 5# of the
switch  sequences, which may affect BCL6 expression (Stav-
nezer et al., 1985; Li et al., 1994). Together, these data showed
that exogenous BCL6 was detectable in both the GC and
plasma cells of IHABCL6 mice, indicating its transcriptional
deregulation.
Deregulated expression of BCL6 leads to increased GC
formation and perturbed plasmacytoid differentiation
Young (<5 month), immunologically mature IHABCL6 mice
displayed a normal number and distribution of B and T cells
and a normal architecture of all lymphoid organs, including thy-
mus, spleen, lymph nodes, and gut-associated lymphoid tis-
sue. However, the same mice displayed a small (20%–50%),
but significant, reduction in total serum immunoglobulin levels
of all subclasses—except for IgM—both under basal condi-
tions and after immunization with T-dependent antigens (NP)
(Supplemental Figures S1A and S1B). Despite these defects,
affinity maturation appeared normal (Supplemental Figure S1C),
suggesting that SHM was unaffected. IHABCL6 mice dis-
played also a w30% reduction in the number of total plasma-
cytoid cells (B220+/− CD138+), mainly due to a decrease inCANCER CELL : MAY 2005
A R T I C L EFigure 1. Generation of IHABCL6 knockin mice
A: Targeting strategy. The murine germline Ig heavy chain (IgH) locus is shown before (top scheme) and after (middle scheme) homologous recombination
with the targeting vector, which contains a murine BCL6 cDNA downstream and in frame with a hemagglutinin (HA) tag, a neomycin-resistance (neo)
gene under the control of the PGK promoter and flanked by two loxP sites, and the thymidine kinase gene (HSV-TK) for positive selection of the transfected
cells. The final configuration of the recombined allele after cre-mediated excision of the neo cassette in vitro is shown at the bottom. Expected restriction
fragments and probes used for Southern blotting are also indicated. E, immunoglobulin heavy chain intronic enhancer; I, immunoglobulin mu sterile
transcript promoter; C, the four C exons; S, switch mu region.
B: Southern blot analysis of BamHI-digested ES cells DNA from wild-type (wt) and homologous recombinant clones before (M) and after () Cre mediated
recombination. On the right, BamHI-digested tail DNA from F1 offspring.post-CSR plasma cells (IgM−IgD−), while IgM+IgD+ plasma cells
are normal (Supplemental Figure S2). These findings indicate
that deregulated BCL6 expression is compatible with normal
CSR and plasmacytoid differentiation, although it favors the
production of IgM-secreting plasma cells (see Discussion).
We then evaluated the GC responses (size and number of
GC) of IHABCL6 and wt littermates by flow cytometric analy-
sis of PNA expression and in situ IHC staining for PNA/BCL6
on spleens obtained from mice before and after immunization
with SRBC. As expected, unimmunized wt mice displayed a
very limited number of scarcely developed GCs that increased
significantly upon immunization (Figure 3A). Notably, nonimmu-
nized IHABCL6 mice displayed an increased number of GCs,
comparable to that observed upon immunization of wt mice
(compare the second and third bars from left in Figure 3A). This
significant increase in the number of GCs as well as in the total
GC area persisted when animals were examined 10 days afterCANCER CELL : MAY 2005immunization (bars 3 and 4 from left in Figures 3A and 3B), and
was comparable to that observed in immunized AID−/− mice,
which were used as control as they are known to form enlarged
GCs (Muramatsu et al., 2000) (data not shown). However, the
sizes of GCs were not notably different in IHABCL6 versus
control mice, in contrast to those of AID−/− mice. The analysis
of proliferating (BrdU) or apoptotic (Annexin-V+) B cells indi-
cated that the increased number of GCs in IHABCL6 mice
was not associated with changes in the fraction of proliferating
or dying B cells within the GC (data not shown). Overall, these
data suggest that deregulated BCL6 expression increases the
number of GCs by lowering the threshold for B cells to enter
the GC reaction.
To gain further insight into the mechanism of increased GC
formation, we constructed mice expressing exclusively the
IHABCL6 allele in the absence of endogenous BCL6 alleles.
To this end, we bred the IHABCL6 allele into BCL6−/− mice,447
A R T I C L EFigure 2. Expression of the HABCL6 protein in IHABCL6 mice
A: Northern (left) and Western (right) blot analysis for BCL6 expression in thymus, CD19+, and CD19− splenic cells purified from IHABCL6 mice and wild-
type (wt) littermates. A BCL6 cDNA probe detected endogenous BCL6 mRNA in thymus and CD19+ B cells of both wt and knockin mice, as expected. A
band corresponding to the size of the exogenous mRNA transcript is detected only in CD19+ cells of the knockin mice. An analogous pattern of expression
is observed by WB analysis using anti-HA (exogenous) and anti-BCL6 (exogenous+endogenous) antibodies on the same cell populations. Ramos cells
stably transduced with a HA-BCL6 retroviral vector are shown as control. β-actin monitors the loading.448 CANCER CELL : MAY 2005
A R T I C L Eaggregate in typical GC structures, most likely because BCL6 a minority of non-DLBCL lymphomas (not shown). BCL6 ex-
B: Serial spleen sections of SRBC-immunized wt and IHABCL6 knockin mice stained with anti-BCL6 (top) and anti-HA (bottom) antibodies. For each
genotype, images are shown at low (scale bar 40 m, left panel) and high (scale bar 10 m, right panel) magnification.
C: Double immunostaining of spleen sections from wt and IHABCL6 mice with BCL6 (blue) and the plasma cell marker CD138 (brown) (scale bar 5 m).
D–E: Double immunostaining of gut sections (Peyer’s patches) from wt (left) and IHABCL6 (right) animals, with markers color-coded as indicated along
the right side: CD138/BCL6 (D, top), CD138/HA (D, bottom), BCL6/IgA (E, top), and BCL6/IgG1 (E, bottom) (scale bar 1 m).Figure 3. Increased GC formation in IHABCL6 mice
A: The total number of GCs before and after SRBC immunization was esti-
mated in spleen sections from wt and IHABCL6 littermates stained with
anti-BCL6 and anti-PNA antibodies, and normalized to the total spleen
area analyzed (top). The ImageJ software (RSB, NIH, Washington, DC) was
used to determine the total area of GCs, defined as BCL6 positive aggre-
gates and expressed as Kpixels (1,000 pixels) (bottom). Error bars indicate
standard deviations.
B: BCL6 staining of representative spleen sections from the mice indicated
in A.which lack GCs (Ye et al., 1997; Dent et al., 1997). Analysis of
lymphoid organs upon SRBC immunization showed that ex-
pression of the exogenous HABCL6 protein in IHABCL6/
BCL6−/− mice was sufficient to induce the proliferation of B
cells, as documented by the appearance of a substantial num-
ber of cells expressing the proliferation marker Ki67 (Figure 4,
top panels). These cells also coexpress the GC-associated
marker PNA, suggesting that they represent bona fide GC B
cells (Figure 4, bottom panels). However, these cells did notCANCER CELL : MAY 2005is needed in other non-B cells necessary for GC formation (Ye
et al., 1997; Dent et al., 1997). The IHABCL6 knockin allele
was unable to rescue the inflammatory phenotype of BCL6−/−
mice (Ye et al., 1997; Dent et al., 1997), also in keeping with its
absence from T cells and antigen presenting cells (not shown).
These results suggest that one effect of deregulated BCL6 ex-
pression is to allow a proliferative GC phenotype in B cells.
Early benign lymphoproliferative disease
in IHABCL6 mice
When sacrificed at 6 months of age, a modest splenomegaly
was noted in a fraction (4/24, 17%) of IHABCL6 mice. Micro-
scopic analysis showed evidence for abnormal B cell expan-
sions involving predominantly the spleen, but also the lymph
nodes, in all three lines (overall, 10/24 [42%] IHABCL6 ani-
mals versus 2/18 [11%] wt controls; range = 33 to 83% in the
3 lines). These abnormalities were represented by a partial ef-
facement of the follicular architecture with the appearance of
blast cells (Figure 5, second panel from left). Immunostaining
of spleen populations indicated that the expanded white pulp
zones were composed predominantly of B cells, but also in-
cluded disorganized accumulations of other cell types such as
T cells and dendritic cells. These abnormal expansions were
polyclonal/oligoclonal upon analysis of their rearranged endog-
enous Ig genes (see below), and displayed a normal karyotype
(data not shown). Taken together, these features are compati-
ble with a diagnosis of benign lymphoproliferative disease
(LPD). In addition, 4 of the 24 (17%) IHABCL6 mice analyzed
at this age displayed a complete effacement of the splenic lym-
phoid architecture due to the proliferation of large lymphoid
cells, consistent with a diagnosis of DLBCL (see below). The B
cell population enriched in the LPD (IgMhigh-IgDlow B cells,
which are negative for both CD23 and CD21) appears to be
predominant in some DLBCL (compare second and third pan-
els from left in Supplemental Figure S3B), suggesting that it
may be progressively selected during tumorigenesis. Overall,
these morphological and phenotypic criteria, together with the
temporal evolution toward clonality, suggest that the LPD may
represent a stage toward the development of DLBCL (see Dis-
cussion).
Development of DLBCL in IHABCL6 mice
Starting at approximately 13 months of age, IHABCL6 mice
showed increased mortality, such that only w80% of the ani-
mals survived at 15 months (p value < 0.01) (Figure 6A). Histo-
logic examination of 79 knockin mice and 84 wt littermates
between 15 and 20 months of age revealed that 36% (5H7 line)
to 62% (4E12 line) of the animals had developed clonal B cell
lymphomas, predominantly of splenic origin, with or without
nodal involvement (Figure 6B). These tumors displayed a ma-
ture B cell phenotype (IgM+IgD+CD43−), and most were histo-
logically reminiscent of the human DLBCL (75% of cases), with449
A R T I C L EFigure 4. Introduction of the IHABCL6 allele in
a BCL6-deficient background results in reap-
pearance of proliferating B cells with GC phe-
notype
Serial sections of Peyer’s patches from wt,
BCL6−/−, BCL6−/−/IHABCL6, and IHABCL6 mice
immunized with SRBC. Top panels: double
immunostaining with PNA (brown) and the pro-
liferation marker Ki67 (blue) (scale bar 10 m,
inset 1 m). Bottom panels: double immuno-
staining with PNA and HA (scale bar 10 m, inset
1 m).pression in these tumors was heterogeneous, ranging from
high expression detectable by IHC (Figure 5, right panel) to
levels below detectability by IHC. Notably, molecular analysis
of the rearranged IgV genes from eleven lymphoma biopsies
confirmed their clonal derivation (Figure 6C) and revealed the
presence of somatic mutations in 9/11 (82%) cases studied
(Supplemental Table S1), indicating that these tumors have
transited through the GC. Additional IHC and flow cytometric
analysis indicated that these tumors express IgM in most of the
cases, lack the plasmacytoid marker CD138, and have variable
expression of MUM1/IRF4 (Supplemental Figure S3A), a
marker identifying a subset of late and activated GC
centrocytes in humans (Falini et al., 2000). Overall, this pheno-
type is consistent with a GC derivation, with variable expres-
sion of late GC markers, analogous to a large fraction of human
DLBCL (see Discussion). Spectral karyotype (SKY) analysis re-
vealed complex nonrandom cytogenetic abnormalities in 14/16
tumors analyzed, including 13 DLBCLs and one marginal zone
lymphoma (Supplemental Table S2). These clonal karyotypic
aberrations comprised both numerical and structural aber-
rations, and in most cases (13/14) involved chromosome 15,
either by trisomy (n = 12) or by translocation (t[12;15] in one
case, both spleen and thymus) (Figure 6D). Trisomy of chromo-450some 13 was the second most frequent abnormality, with 7/14
positive cases, and was recurrently seen in association with
trisomy 15.
In summary, analysis of the three independent IHABCL6
lines uncovered alterations in B cell proliferation (LPD and/or
lymphoma) by the age of 20 months in 76%–89% of mice. In
contrast, a very low background incidence of lymphomas was
observed in wt littermates (Figure 6B).
Discussion
Implications for the biological functions of BCL6
In vitro studies indicate that BCL6 maintains the GC phenotype
of B cells by preventing premature cell cycle arrest, differentia-
tion, and death (Shaffer et al., 2000; Niu et al., 2003; Tunyaplin
et al., 2004). The results herein suggest that BCL6 may also be
involved in the establishment of the GC reaction. The observa-
tion that nonimmunized mice expressing deregulated BCL6
can form GCs in numbers comparable to those observed in wt
mice upon immunization (Figure 3A) suggests that BCL6 may
control the threshold allowing B cells to enter GC formation.
Specifically, BCL6 appears to lower the threshold for B cells to
enter the cell cycle, since B cell-restricted expression of BCL6CANCER CELL : MAY 2005
A R T I C L EFigure 5. Development of LPD and DLBCL in
IHABCL6 mice
Spleen sections of wt (left) and IHABCL6 mice
displaying LPD (middle) or overt DLBCL (right
two panels) were stained with H&E or double
immunostained with BCL6 (blue) and B220
(brown) as indicated (top and bottom panels,
scale bar 10 m; middle panels, scale bar
1 m).in otherwise BCL6 null mice leads to the reappearance of pro-
liferating B cells with GC markers upon immunization (Figure
4). This notion is also consistent with the observation that B
cells expressing an inactive BCL6 molecule, i.e., a truncated
BCL6 allele lacking 4 of the 6 zinc finger DNA binding domains
and incapable of nuclear localization and DNA binding, remain
alive and quiescent in vivo (Ye et al., 1997). Recent data imply
that BCL6 may favor proliferation by directly inhibiting the tran-
scription of the cell cycle arrest genes p53 and p21 (Phan and
Dalla-Favera, 2004, and unpublished data). Together, these ob-
servations suggest that the biologic function of BCL6 may be
to promote GC formation by ensuring that signals such as
those from the antigen and the CD40 receptor, which can alter-
natively induce proliferation, differentiation, or death, are li-
censed only for proliferation.
The results shown here also have specific implications for
the role of BCL6 in controlling the differentiation of B cells to
plasma cells. Based on in vitro data, it has been proposed that
BCL6 expression blocks plasma cell differentiation and that
this may occur via transcriptional repression of the BLIMP1
gene, which encodes a transcription factor required for the
generation of all types of plasma cells (Reljic et al., 2000; Shaf-
fer et al., 2002; Tunyaplin et al., 2004). Indeed, it was shown
recently that constitutive BCL6 expression can reprogram the
phenotype of plasma cells toward B cells in cell lines in vitro
(Fujita et al., 2004). However, the phenotype of IHABCL6 mice
suggests that the relationship between BCL6 expression and
plasma cell differentiation may be more complex in vivo. These
mice have a normal number of morphologically and immu-
nophenotypically (CD138+) normal IgM+ plasma cells, which
secrete normal levels of immunoglobulins. This result suggestsCANCER CELL : MAY 2005that constitutive BCL6 expression is compatible with plasma
cell differentiation in vivo. However, the number of post-CSR
plasma cells and both the basal and postimmunization serum
levels of most Ig isotypes—except IgM—are slightly decreased
in these mice. These alterations can be attributed at least in
part to the modulatory activity of BCL6 on switching to various
Ig isotypes via transcriptional repression of the sterile tran-
scripts required for CSR (Harris et al., 1999). However, it re-
mains possible that BCL6 inhibits isotype-switched plasma
cell differentiation, and that the presence of plasma cells in
IHABCL6 mice reflects nonubiquitous activity of the I pro-
moter, leading to an escape toward plasmacytoid differentia-
tion by B cells lacking HABCL6 expression. In conclusion,
while our results seem to exclude a general role for BCL6 in
inhibiting plasma cell differentiation in vivo, its role in con-
trolling the generation of isotype-switched plasma cells re-
mains to be further elucidated.
Implications for the role of deregulated BCL6
in DLBCL pathogenesis
The spontaneous, high-penetrance development of B cell-
derived lymphoproliferations in IHABCL6 mice defines BCL6
as an oncogene capable of inducing B cell lymphomas in vivo.
A recent report described BCL6 transgenic mice that develop
lymphomas, appearing at significant frequency only upon treat-
ment with mutagens and mostly derived from T cells (Baron
et al., 2004). It is likely that the phenotype of our mice better
recapitulates human BCL6-mediated neoplasia due to the dif-
ferent strategy applied to achieve deregulated BCL6 expres-
sion. In particular, with the “knockin” approach described here,
we sought to reproduce the specific structural and regulatory451
A R T I C L EFigure 6. Characteristics of DLBCL in IHABCL6 mice
A: Kaplan-Meyer event-free survival in IHABCL6 mice and wt littermates.
B: Incidence of B-NHL (red) and LPD (orange) in three IHABCL6 lines (4E12, 5H7, and 4B8) at 15–18 months of age, as compared to their wt littermates.
The total number of mice analyzed in each group is indicated. Statistical analysis was performed using the χ2 test, and the corresponding p values are
given in brackets (see also Experimental Procedures).
C: IgV gene amplification from representative samples diagnosed as LPD (top gel, lanes 2–6) or DLBCL (bottom gel, lanes 1–6). MW, molecular weight
marker; a clonal tumor population was loaded as control on lane 1 of the top gel. While three major bands, indicative of polyclonal rearrangements (see
Experimental Procedures), are visible in each LPD sample, a single PCR product could be amplified from the DLBCL samples, each showing a discrete size
and confirmed to be monoclonal by sequencing analysis.
D: SKY analysis on metaphase spread from tumor cells of IHABCL6 mouse 4B8-22, carrying a DLBCL; a chromosomal translocation involving chromosomes
12 and 15 and a trisomy of chromosome 11 are shown.features that characterize one of the chromosomal transloca-
tions observed in human DLBCL. Our results clearly indicate
that BCL6 deregulation in mice can elicit B cell tumors resem-
bling human DLBCL, even in the absence of exogenous mu-
tagens.
The natural history of neoplastic progression observed in
IHABCL6 mice suggests that tumor development proceeds
in at least two definable stages. The poly/oligoclonal, karyotyp-
ically normal LPD that develops early in life may represent a
premalignant condition that precedes DLBCL formation. This
hypothesis is supported by the temporal relationship between
these two pathologic entities, as well as by morphological and
phenotypic criteria (see Results). The pathological picture of
LPD is complex, and has not been described so far in humans.
This picture does not resemble follicular lymphoma, consistent
with the notion that BCL6 deregulation in humans is associated
predominantly with the de novo form of DLBCL, as opposed
to the form of DLBCL that derives from follicular lymphoma
(Dalla-Favera and Gaidano, 2001).
The kinetics of DLBCL formation and the clonality of the452developing tumors indicate that, analogous to most tumor
models, a single oncogenic hit is not sufficient for lymphoma-
genesis, and that deregulation of BCL6 needs to be comple-
mented by additional genetic or epigenetic factors. Interest-
ingly, repeated injections over the animal lifetime with potent
polyclonal antigenic stimuli (SRBC; see Experimental Pro-
cedures) did not influence LPD or DLBCL development (data
not shown), suggesting that chronic/repeated antigenic stimu-
lation, an often-discussed factor in various types of human
lymphoid malignancies, may not play a significant role in
DLBCL pathogenesis. Conversely, the recurrent association
with specific chromosomal abnormalities in murine DLBCL,
such as trisomy 15 and trisomy 13, suggests that tumor pro-
gression occurs mostly through the accumulation of additional
genetic lesions. The precise consequences of these whole-
chromosome trisomies are not clear; however, trisomy 15—a
commonly observed abnormality in murine B cell lympho-
mas—does not appear to target cMYC, whose expression was
found to be heterogeneous and not significantly higher in
DLBCL carrying this lesion (data not shown). Also, the pres-CANCER CELL : MAY 2005
A R T I C L Eence of reciprocal chromosomal translocations suggests that,
analogous to human DLBCL, some of these lesions may arise
from mistakes in the Ig remodeling mechanisms (CSR and
SHM) that normally occur within the GC (Küppers and Dalla-
Favera, 2001). It has been recently reported that BCL6 sup-
presses p53-dependent responses to DNA breaks within the
GC, thus allowing GC cells to tolerate the physiologic DNA
breaks associated with CSR and SHM (Phan and Dalla-Favera,
2004). Thus, deregulated BCL6 expression may exert its onco-
genic functions directly, by favoring constitutive proliferation
and increased GC entry, as well as indirectly, by maintaining an
increased number of B cells in a p53-negative, recombination-
permissive GC environment.
A mouse model of DLBCL
Mouse models that precisely recapitulate the genetics and bi-
ology of human cancers represent much-needed tools for
pathogenetic studies and for preclinical therapeutic testing.
While numerous mouse models of B cell lymphoma exist, most
of them have been obtained by introducing genetic lesions that
are not found in human tumors and exert their oncogenic activ-
ity in immature B cells as opposed to GC B cells, the normal
counterpart of most human B cell lymphomas (Dalla-Favera
and Gaidano, 2001; Küppers et al., 1999). In particular, only
two models of GC-derived lymphomas resembling DLBCL are
available, obtained by deregulating TCL1 and by deleting BAD,
respectively (Hoyer et al., 2002; Ranger et al., 2003). However,
neither of these two models recapitulates the genetics, and
therefore possibly the biology, of human DLBCL, since the
TCL1 and BAD genes are not primarily altered in human
DLBCL. In contrast, IHABCL6 mice represent credible models
of human DLBCL because: (1) they have been generated by
transcriptional deregulation of BCL6, mimicking the outcome
of the genetic lesion most commonly associated with DLBCL,
(2) deregulation was achieved using the same promoter found
to be juxtaposed to BCL6 in a recurrent DLBCL-associated
chromosomal translocation, and (3) the resultant tumors dis-
play morphologic and immunophenotypic features typical of
human DLBCL—most notably, they derive from the GC, as un-
equivocally demonstrated by the presence of hypermutated
IgV genes. As faithful models of human DLBCLs, IHABCL6
mice will be useful for studying the pathogenesis of this com-
mon tumor, including its early stages that go undetected in
humans but can be analyzed at the LPD stage in mice. Given
the increasing evidence that BCL6 represents a therapeutically
targetable molecule (Bereshchenko et al., 2002; Polo et al.,
2004), these mice are likely to constitute valuable preclinical
models for the testing of novel therapeutic regimens specific
for DLBCL.
Experimental procedures
Targeting vector construction and generation
of IHABCL6 knockin mice
The IHABCL6 targeting vector was constructed in multiple steps by sub-
cloning a HA-tagged murine BCL6 cassette into the pPNT vector, down-
stream of the IgH I promoter (1.1Kb PCR fragment) and 5# to a loxP-
flanked stop cassette containing a neomycin-resistance gene (neoR). Aw10
Kb EcoRI fragment including the four C exons was then isolated from
pEco1.1C vector (gift of F. Alt, Harvard Medical School, Boston, MA) and
subcloned downstream to the neoR cassette. The targeting vector was
electroporated in the embryonic stem (ES) cell line Sv129, and Neo-resis-
tant, homologous recombinant clones were identified by Southern blotCANCER CELL : MAY 2005analysis of BamHI-digested DNA, using 5# (JH) and 3# (C1-2) probes; hy-
bridization with a Neo probe confirmed that only one recombination event
had occurred. After Cre mediated excision of the neoR cassette in vitro by
transient transfection of a Cre-expressing plasmid, homologous recombi-
nant ES cell clones were injected into blastocysts from C57BL/6 mice.
Chimeric mice obtained from 3 independent ES clones transmitted the
knockin allele through the germline and were all backcrossed onto a
C57BL/6 background (1–8 generations) to generate lines 4E12, 5H7, and
4B8. Mice were genotyped by Southern blot analysis of BamHI-digested
genomic DNA using the 3# probe or by PCR analysis using oligonucleotides
5#HA (5#-ATG GCC TAC CCA TAC GAC GTC-3#) and mBCL6-473c (5#-TGA
ACT TCC TGC ATG TGT CGA-3#).
Tumor-free survival and statistical analysis
Mice were housed and sacrificed according to the regulations of the Depart-
ment of Veterinary Medicine, Columbia University. Tumor watch studies
were conducted on animals in a mixed (Sv129xC57/BL6) background (i.e.,
the second and third backcross generations for the line 4E12 and the first
and second backcross generation for the lines 5H7 and 4B8). Within each
line, comparable numbers of age-matched wt littermates controlled for pos-
sible differences in lymphoma incidence. Animals were monitored for a min-
imum of 18 months and a subgroup analyzed every 6 months for the pres-
ence of abnormalities. Mice that survived the duration of the study were
sacrificed, and a necropsy was performed. When possible, necropsies were
performed on dead animals to determine whether they had gross evidence
of tumors. Statistical analysis was performed on the Statview program (SAS
Institute Inc., Cary, NC) using Kaplan-Meier cumulative survival and the log-
rank (Mantel-Cox) test to determine whether differences were significant.
The χ2 test was used to compare B-NHL incidence in IHABCL6 knockin
mice versus wt littermates.
Mice immunization
For analysis of T cell-dependent immune responses, age- and sex-matched
mice were immunized intraperitoneally at w8 weeks of age with 0.5 ml of
a 2% SRBC suspension in PBS (Cocalico Biologicals, PA), and sacrificed
after 10 days. For tumor development survey, a cohort of animals was kept
under repeated antigenic stimulation by injecting SRBC every 3 weeks until
death or tumor development.
Northern blot and Western blot analysis
CD19+ and CD19− splenic B cells were isolated by a magnetic cell separa-
tion protocol using MACS columns (Miltenyi Biotech, Auburn, CA). Total
RNA was extracted from thymus, CD19+, and CD19− B cells using the Trizol
reagent (Invitrogen Life Technologies, Carlsbad, CA), and Northern blot
analysis for BCL6 expression was performed as described (Cattoretti et al.,
1995). Total protein extracts were prepared from the above cell populations
using RIPA buffer, gel electrophoresed on 4%–12% gradient SDS/PAGE
gels (Invitrogen), transferred to nitrocellulose membranes (Sheller &
Schuell), and immunostained according to standard methods using anti-
BCL6 (N3) rabbit polyclonal Abs (Santa Cruz Biotechnology, Santa Cruz,
CA), anti-HA rat monoclonal Abs (Covance, Princeton, NJ), and an anti-β
actin Ab (AC15, Sigma, St. Louis, MO) as control for loading (Cattoretti
et al., 1995). Proteins were detected using the ECL reagents (Amersham
Biosciences) as recommended by the manufacturer.
Flow cytometry
The following antibody combinations were used on single cell suspensions
from normal organs or tumors: A: B220, IgM, IgD, Ig kappa light chain; B:
B220, CD23, CD21, CD11b; C: IgM, CD43, CD5, CD19; D: B220, CD138,
IgM, IgD, Ig kappa light chain; E: B220, CD69, CD80; F: B220, A44.1, IgM,
CD43; G: CD3, CD4, CD8. The enumeration of GC-type of cells was per-
formed by four-color staining with B220, PNA, CD38, and GL7. All antibod-
ies were from BD Pharmingen (San Diego, CA), except for the IgD-Pe
(Southern Biotechnology Inc., Birmingham, AL). Data were acquired on a
FACSCalibur (Becton Dickinson) and analyzed with CELLQuest software.
Histology, immunohistochemistry, and immunofluorescence
Four m-thick formalin-fixed, paraffin-embedded sections were stained for
H&E or immunostained as published previously (Ye et al., 1997), using the
following primary antibodies: rabbit anti-BCL6 (N3), goat anti-IRF4, goat453
A R T I C L Eanti-Pax5, mouse IgG1 anti Pax5 (Santa Cruz Biotechnology, Santa Cruz,
CA), donkey anti IgM (Jackson Immunoresearch Laboratories, West Grove,
PA), mouse IgG1 anti BCL6 (Novocastra Laboratories, Newcastle upon
Tyne, UK), rat anti B220, CD138 (BD Pharmingen), HA (Roche Applied Sci-
ences, Indianapolis, IN), PNA lectin (Vector, Burlingame, CA). Double immu-
nohistochemical stainings were performed as published previously (Catto-
retti et al., 1995) with noncrossreacting combinations of primary and
secondary antibodies.
Somatic hypermutation analysis
Genomic DNA was isolated from tumor specimens by the salting-out
method, and the rearranged VH sequences were amplified by PCR, using
forward primers that anneal to the framework region III of the most abun-
dantly used VH J558 family or to the VH7183 family, and reverse primers
positioned in the JH3 or JH4 intron in separate reactions (Jolly et al., 1997).
PCR conditions were 94°C for 30 s, 63°C for 30 s and 72°C for 2 min, for
35 cycles. Using this protocol, a polyclonal B cell population can be de-
tected as three major PCR fragments (four if the reverse JH4 primer is
used), corresponding to cells where the JH1, JH2, JH3 (and JH4) segments
were rearranged. Conversely, a clonal population (e.g., a tumor) gives either
a unique band (the tumor clone) or a predominant band over a faint back-
ground (residual nontumor cells in the sample). PCR products were gel-
purified using the QIAQUICK purification method (QIAGEN) and sequenced
directly on a ABI377 sequencer. Sequences were compared to the NCBI
databases and to our own database to rule out polymorphisms as well as
contamination with previously amplified rearrangements.
SKY
Multicolor spectral karyotyping was performed on representative spleen
and tumor specimens according to standard procedures (Harris et al.,
2003).
Supplemental data
Supplemental data for this article can be found at http://www.cancercell.
org/cgi/content/full/7/5/445/DC1/.
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